Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Non-Interventional Study.
- Who it may be relevant to
- Registry conditions: Prostate Carcinoma. Basic parameters: from 18 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). By collecting biological samples (like blood, urine, and tissue), and health information (such as treatment, diet, and quality of life) researchers hope to learn more about prostate cancer and ways to improve outcomes in the future.
Detailed description
PRIMARY OBJECTIVE:
I. To create an annotated biorepository with prospectively collected blood and urine samples from men with advanced prostate cancer.
OUTLINE: This is an observational study.
Patients undergo blood and urine sample collection, complete surveys, and have their medical records reviewed on study.
Interventions
- Other Non-Interventional Study
Non-interventional study
Primary outcome measures
- Collection of biological specimens and clinical data for future research related to prostate cancer. [Time frame: Up to 5 years]
Eligibility criteria
Inclusion criteria
- Men of all racial and ethnic groups 18 years of age or older
- Men with a diagnosis of advanced (metastatic) prostate cancer who are scheduled to begin a new systemic treatment (including first or subsequent lines of therapy)
- Prior participation on clinical trials is allowed
Exclusion criteria
- Inability to give informed consent
- Any other malignancy, unless previously treated with curative intent and the subject has been disease free for 3 years or longer
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 2 centers
- Los Angeles General Medical Center — Los Angeles
- USC / Norris Comprehensive Cancer Center — Los Angeles
Identifiers
NCT: NCT06067295 · 4P-22-2 · NCI-2023-01434 · 4P-22-2 · P30CA014089